Cancerous disease modifying antibodies

Details Cancerous disease modifying antibodies Cancerous disease modifying antibodies

A - Human Necessities

61

K

A61K 39/395 (2006.01) A61K 47/48 (2006.01) A61K 51/10 (2006.01) A61P 35/00 (2006.01)

Patent

CA 2579900

The use of a cancerous disease modifying antibody (CDMAB) 10A304.7 for treating a tumour in humans and methods of isolating and producing CDMABs. The monoclonal antibody 10A304.7 (ATTC accession number PTA-5065) is cytotoxic to cancer cells, wherein cytotoxicity is mediated via antibody dependant cell mediated cythotoxicity (ADCC) and complement-dependant cytotoxicity (CDC). The monoclonal antibody 10A304.7 is useful for delaying the dicease progression of a human tumor.

L'invention concerne l'utilisation d'un anticorps modificateur d'une maladie cancéreuse (CDMAB) 10A304.7 pour traiter une tumeur humaine et des procédés d'isolement et de production de CDMAB. L'anticorps monoclonal 10A304.7 (numéro d'entrée PTA-5065 à l'ATCC) a une action cytotoxique sur les cellules cancéreuses, la cytotoxicité étant induite par une cytoxicité à médiation cellulaire dépendante des anticorps (ADCC) et par une toxicité dépendante du complément (CDC). L'anticorps monoclonal 10A304.7 sert à retarder la progression de la maladie provoquée par une tumeur humaine.

Affiliated with

Also associated with

Rating

Cancerous disease modifying antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cancerous disease modifying antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cancerous disease modifying antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1922614